Cellectar Biosciences has announced the ongoing median overall survival (mOS) of patients in the Phase 1 trial investigating CLR 131 in relapsed and refractory myeloma. A mOS of 26.2 months has been reported for patients in cohort 1. These patients received a single dose of 12.5mCi/m2, and had received an average of 5.8 previous treatments. Positive results have also been observed in cohorts 2 and 3 in which patients received a single dose of 18.75mCi/m2 and 25mCi/m2 respectively. This trial is ongoing, therefore the mOS may continue to increase for all patient cohorts.
CLR 131, which is a phospholipid-drug conjugate, is not currently being investigated as a treatment for myeloma patients in the UK.